By Dr Charles Edo de Bock

Conference Abstracts

Lock RB; Toscan CE; McCalmont H; Evans K; Doculara L; Kosasih HJ; Gifford AJ; Ashoorzadeh A; Lin X; Trahair TN; De Bock CE; Patterson AV; Smaill JB, 2023, 'The AKR1C3-Activated Prodrug, Achm-025, Eradicates Disease in Preclinical Models of Aggressive T-Cell Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, Vol. 142, pp. 4251 - 4251, http://dx.doi.org/10.1182/blood-2023-181298

Murray H; Enjeti AK; Kahl R; Flanagan H; Skerrett-Byrne D; Al-Mazi J; Smith N; de Bock C; Larsen M; Verrills N; Dun M, 2020, 'Phosphoproteomics Uncovers Synergy between DNA-PK and FLT3 Inhibitors in Acute Myeloid Leukaemia', in BLOOD, AMER SOC HEMATOLOGY, ELECTR NETWORK, Vol. 136, presented at 62nd Annual Meeting of the American-Society-of-Hematology (ASH), ELECTR NETWORK, 05 December 2020 - 08 December 2020, http://dx.doi.org/10.1182/blood-2020-142435

Loontiens S; Durinck K; Vanhauwaert S; Depestel L; Oliveira ML; Dewyn G; De Bock C; Barata JT; Langenau D; Cools J; Taghon T; Van Vlierberghe P; Speleman F, 2019, 'PHF6loss drives IL7R oncogene addiction in TLX1 driven T-ALL', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3696

Govaerts I; Gielen O; Habets R; de Bock C; De Keersmaecker K; Segers H; Uyttebroeck A; Maertens J; Boeckx N; De Strooper B; Cools J, 2019, 'PF159 COMBINATION OF SELECTIVE GAMMA‐SECRETASE INHIBITOR MRK‐560 WITH OTHER TARGETED THERAPY IS AN EFFECTIVE AND SAFE TREATMENT FOR T‐ALL', in HemaSphere, Wiley, Vol. 3, pp. 31 - 31, http://dx.doi.org/10.1097/01.hs9.0000558852.50584.54

Verbeke D; de Bock C; Demeyer S; Prieto C; De Bie J; Gielen O; Mentens N; Daelemans D; Uyttebroeck A; Boeckx N; De Keersmaecker K; maertens J; Segers H; Cools J, 2019, 'PF165 THE XPO1 INHIBITOR KPT‐8602 WORKS SYNERGISTIC WITH DEXAMETHASONE TO INHIBIT ACUTE LYMPHOBLASTIC LEUKEMIA CELLS', in HemaSphere, Wiley, Vol. 3, pp. 34 - 35, http://dx.doi.org/10.1097/01.hs9.0000558876.81078.b9

Van Thillo Q; De Bie J; Demeyer S; Tam WL; Sweron B; Geerdens E; Gielen O; Segers H; Boeckx N; Uyttebroeck A; Cools J; de Bock CE, 2019, 'PS916 TCF7-SPI1 AND NRAS (G12D) COOPERATE IN THE DEVELOPMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA', in HemaSphere, Wiley, Vol. 3, pp. 413 - 413, http://dx.doi.org/10.1097/01.hs9.0000561944.30888.3a

de Bock C; Habets R; Serneels L; Lodewijckx I; Verbeke D; Nittner D; Narlawar R; Demeyer S; Dooley J; Liston A; Taghon T; de Strooper B; Cools J, 2019, 'PS917 SAFE TARGETING OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BY SUBUNIT SELECTIVE GAMMA-SECRETASE INHIBITION', in HemaSphere, Wiley, Vol. 3, pp. 413 - 414, http://dx.doi.org/10.1097/01.hs9.0000561948.38512.48

Loontiens S; Durinck K; Vanhauwaert S; Depestel L; Oliveira ML; Dewyn G; de Bock C; Barata JT; Langenau D; Cools J; Taghon T; Van Vlierberghe P; Speleman F, 2019, 'PS920 PHF6 LOSS DRIVES IL7R ONCOGENE ADDICTION IN TLX1 DRIVEN T‐ALL', in HemaSphere, Wiley, Vol. 3, pp. 414 - 415, http://dx.doi.org/10.1097/01.hs9.0000561956.76629.c7

Broux M; Prieto C; Demeyer S; Vanden Bempt M; Alberti‐Servera L; Vandepoel R; Mentens N; Gielen O; Jacobs K; Geerdens E; Vicente C; de Bock CE; Cools J, 2019, 'S858 SUZ12 INACTIVATION COOPERATES WITH JAK3 MUTANT SIGNALING TO DRIVE T‐ALL DEVELOPMENT', in HemaSphere, Wiley, Vol. 3, pp. 383 - 384, http://dx.doi.org/10.1097/01.hs9.0000561712.29231.fb

Back to profile page